VIP (Vasoactive Intestinal Peptide)
Human observationalAlso known as: Aviptadil, Vasoactive Intestinal Polypeptide
Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
A signalling peptide with broad anti-inflammatory and vasodilatory roles. Its synthetic form (aviptadil) has been investigated for lung conditions; intranasal VIP appears in off-label chronic-inflammatory (CIRS) protocols with limited formal evidence.
Mechanism
Acts on VPAC receptors to relax smooth muscle, modulate immune signalling and influence pulmonary and vascular tone.
Evidence
Mixed: aviptadil has been trialled for respiratory illness with inconsistent results; the intranasal wellness use rests largely on a single clinician's protocol and anecdote.
Community-reported information
Off-label compounded use varies. Anecdotal and unvalidated; general information only.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
Very short (minutes) for native VIP.
Storage
Refrigerate solutions.
Commonly reported side effects
- Flushing
- Low blood pressure
- Diarrhoea
- Headache
Legal status by region
- USAviptadil investigational; nasal VIP compounded off-label.
- GBNot licensed for general use.
Legal status changes over time; verify locally before relying on this.
Citations
- VIP / aviptadil researchPubMed